MTIM
AKBA icon

Marathon Trading Investment Management’s Akebia Therapeutics AKBA Stock Holding History

Marathon Trading Investment Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-52,651
Closed -$53.7K – 275
2024
Q2 		$53.7K Sell
52,651
-207,350
-80% -$256K ﹤0.01% 246
2024
Q1 		$476K Buy
+260,001
New +$416K 0.04% 170

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marathon Trading Investment Management's AKBA Position: Q3 2024 in Review

Marathon Trading Investment Management sold out of Akebia Therapeutics (AKBA) in Q3 2024, closing a stake of 52,651 shares — an estimated $53.7K sold.

Marathon Trading Investment Management first reported a position in AKBA in Q1 2024 and held it in 2 quarters. The position peaked at $476K in Q1 2024. 114 funds tracked by Wall St. Rank hold AKBA as of Q3 2024.

  • Marathon Trading Investment Management reported no remaining Akebia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Marathon Trading Investment Management sold 52,651 Akebia Therapeutics shares in Q3 2024, an estimated $53.7K.
  • Marathon Trading Investment Management first reported a position in Akebia Therapeutics in Q1 2024 and held it in 2 quarters.
  • Marathon Trading Investment Management's Akebia Therapeutics position peaked at $476K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2024.

Based on Marathon Trading Investment Management's 13F filing for Q3 2024, filed 7 Nov 2024.